Front Row Advisors LLC reported ARBUTUS BIOPHARMA CORP COM (ABUS) in 17 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 0.17% in 2026 Q1. The latest visible filing shows ABUS at 0.17% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Front Row Advisors LLC's position in ARBUTUS BIOPHARMA CORP COM, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
ABUS was reported at 0.17% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q1 — sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Front Row Advisors LLC reported ABUS across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.
The largest reported portfolio weight for ABUS was 0.17% in 2026 Q1.
The most recent filing on this page is 2026 Q1, when Front Row Advisors LLC reported 110,500 shares, equal to 0.17% of portfolio, with an estimated market value of $497K.
The chart compares Front Row Advisors LLC's quarterly ABUS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent ABUS price moves, Front Row Advisors LLC correctly timed 2 out of 3 reported position changes (67%). The annualised alpha on ABUS relative to SPY over the holding period was +0.8%.